212 related articles for article (PubMed ID: 8440292)
1. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E
Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292
[TBL] [Abstract][Full Text] [Related]
2. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
[TBL] [Abstract][Full Text] [Related]
3. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic modeling of concentration-effect relationships after controlled-release carbidopa/levodopa (Sinemet CR4) in Parkinson's disease.
Nelson MV; Berchou RC; LeWitt PA; Kareti D; Galloway MP
Neurology; 1990 Jan; 40(1):70-4. PubMed ID: 2296385
[TBL] [Abstract][Full Text] [Related]
6. The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Roos RA; Tijssen MA; van der Velde EA; Breimer DD
Clin Neurol Neurosurg; 1993 Sep; 95(3):215-9. PubMed ID: 8242964
[TBL] [Abstract][Full Text] [Related]
7. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.
Pahwa R; Marjama J; McGuire D; Lyons K; Zwiebel F; Silverstein P; Ward R; Koller WC
Mov Disord; 1996 Jul; 11(4):427-30. PubMed ID: 8813223
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
10. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association.
Benetello P; Furlanut M; Fortunato M; Pea F; Baraldo M
Pharmacol Res; 1997 Apr; 35(4):313-5. PubMed ID: 9264047
[TBL] [Abstract][Full Text] [Related]
11. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
12. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.
Hammerstad JP; Woodward WR; Nutt JG; Gancher ST; Block GA; Cyhan G
Clin Neuropharmacol; 1994 Oct; 17(5):429-34. PubMed ID: 9316692
[TBL] [Abstract][Full Text] [Related]
13. Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR).
Makela EH; Cutlip WD
J Neuropsychiatry Clin Neurosci; 1992; 4(2):234-5. PubMed ID: 1627988
[No Abstract] [Full Text] [Related]
14. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G; Liss C; Reines S; Irr J; Nibbelink D
Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Jankovic J; Schwartz K; Vander Linden C
Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
[TBL] [Abstract][Full Text] [Related]
16. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
LeWitt PA
Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Rytary
Mittur A; Gupta S; Modi NB
Clin Pharmacokinet; 2017 Sep; 56(9):999-1014. PubMed ID: 28236251
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Hsu A; Yao HM; Gupta S; Modi NB
J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
[TBL] [Abstract][Full Text] [Related]
19. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Metman LV; Hoff J; Mouradian MM; Chase TN
Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Cedarbaum JM; Kutt H; McDowell FH
Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
